Lab Corp. (LH) Tops Q2 EPS by 1c

LabCorp Announces Agreement To Acquire Sequenom

BURLINGTON, N.C., and SAN DIEGO, July 27, 2016 /PRNewswire/ -- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world's leading healthcare diagnostics company, and Sequenom, Inc. (NASDAQ: SQNM), a pioneer in non-invasive prenatal testing (NIPT) for reproductive health, today announced that they have entered into a definitive agreement and plan of merger under which LabCorp would acquire all of the outstanding shares of Sequenom in a cash tender offer for $2.40 per share, or an equity value of $302 million, which represents a total enterprise value of approximately $371 million, including net indebtedness.... More

LabCorp Announces Agreement to Acquire Sequenom

Acquisition Creates Market Leader in NIPT, Womens Health and Reproductive Genetics

LabCorp CEO: This is exactly the kind of strategic acquisition that LabCorp seeks

BURLINGTON, N.C. & SAN DIEGO--(BUSINESS WIRE)-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the worlds leading healthcare diagnostics company, and Sequenom, Inc. (NASDAQ: SQNM), a pioneer in non-invasive prenatal testing (NIPT) for reproductive health, today announced that they have entered into a definitive agreement and plan of merger under... More

Laboratory Corporation of America® Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance

Q2 Net revenue of $2.4 billion, up 7% over last year Q2 Diluted EPS of $1.91; Q2 Adjusted EPS of $2.31, up 11% over last year 2016 Adjusted EPS guidance raised to $8.60 $8.95, up 9% to 13% over 2015

BURLINGTON, N.C.--(BUSINESS WIRE)-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended June 30, 2016.

Continued strong revenue growth and double-digit adjusted EPS growth demonstrate the soundness of our strategy, said David P. King, chairman and chief executive officer. Our results reflect our customers... More